Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 9,935 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single-arm Clear all

Conditions: Growth Hormone Deficiency
Interventions: Macimorelin, Arginine, Clonidine; Drug · Diagnostic Test
Lead sponsor: AEterna Zentaris; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Tucson, Arizona • Greenwood Village, Colorado • St. Petersburg, Florida + 9 more

Conditions: Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions: PRI-724; Drug
Lead sponsor: Prism Pharma Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Atlanta, Georgia • Worcester, Massachusetts • Albuquerque, New Mexico + 3 more

Conditions: Diabetic Gastroparesis
Interventions: 2400 ThorS-MagNT Stimulations at 1Hz, 2400 ThorS-MagNT Stimulations at 10Hz, Sham Stimulations; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Educational Cancer Intervention, ICF Text Version 1, ICF Text Version 2, ICF Video Version 1, ICF Video Version 2, ICF Video Version 3, ICF Video Version 4, Survey Administration; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Head Injuries, Facial Injuries
Interventions: Bicycle helmet from Bell Sports Inc., Bicycle helmet education only; Other
Lead sponsor: Parkview Hospital, Indiana; Other
Eligibility: 3 Years to 5 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple
Interventions: ICG Intervention, Near Infrared Camera; Drug · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: MASLD, Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Type 2 Diabetes
Interventions: Decision support, Facilitated referral to a cardiometabolic team-based center; Other
Lead sponsor: American College of Cardiology; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Skin Squamous Cell Carcinoma, Metastatic Skin Cancer
Interventions: Avelumab, Cetuximab; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 428
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 274 more

Conditions: Norovirus Infections
Interventions: VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Human Immunodeficiency Virus
Interventions: IMB, Information-Only Control; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 17 Years to 24 Years · Male only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Chronic Lymphocytic Leukemia
Interventions: Bendamustine, Venetoclax, Rituximab; Drug
Lead sponsor: Nicole Lamanna; Other
Eligibility: 18 Years to 99 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors
Interventions: ALKS 4230, Pembrolizumab; Biological
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 17
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more

Conditions: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
Interventions: Genotype-guided dose determination, Non-genotype guided warfarin dosing; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: docetaxel, cetuximab, bortezomib; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Metastatic Colorectal Cancer
Interventions: Encorafenib, Cetuximab, Pembrolizumab; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more

Conditions: Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
Interventions: transbronchial biopsy; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Peripheral Vascular Disease, Hemorrhage
Interventions: EVICEL ™ Fibrin Sealant (Human); Biological
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Jacksonville, Florida

Conditions: Laceration, Abscess
Interventions: Nitrous Oxide; Drug
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 3 Years to 12 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Dental Caries, Dry Mouth, Periodontal Diseases, Bleeding Gum
Interventions: EHR Changes, Medical Staff EHR Training, Clinician CSM theory-based didactic education and skills training, Standard ADA Oral Health Training; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 55 Years and older
Enrollment: 929 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Precocious Puberty, Central
Interventions: Leuprolide Acetate 45 mg; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 2 Years to 9 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 10
States / cities: San Diego, California • Hollywood, Florida • Jacksonville, Florida + 7 more

Conditions: Chronic Idiopathic Urticaria
Interventions: Omalizumab Injection, Xolair Prefilled Syringe; Drug
Lead sponsor: Kashiv BioSciences, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more

Conditions: Asthma
Interventions: Propeller Health device + asthma navigator; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Ischemic Stroke
Interventions: alfimeprase; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Los Angeles, California • Chicago, Illinois • Des Moines, Iowa + 13 more

Search by objective public record fields.

A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

Thoracic Neuromodulation for Diabetic Gastroparesis

Community Enhanced Virtual Informed Consent

Impact of Helmet Use in Preschool Children

Intravenous Indocyanine Green for Localization of Intra-thoracic Lesions

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

Transform CV Risk in Diabetes

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Norovirus Challenge Study

Mobile-health (mHealth) Intervention to Support HIV Self-testing and PrEP Uptake Among Young Men Who Have Sex With Men

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

Genotype-Guided Warfarin Therapy Trial

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions

The Evicel Post-Authorization Surveillance Study

Nitrous Oxide Use in Minor Procedures

Oral Health Intervention in Adult Primary Care

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

Breathing Counts: Evaluating Adherence in the Presence of Asthma Navigation Support

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke